Invivyd Inc. (IVVD) - Net Assets
Based on the latest financial reports, Invivyd Inc. (IVVD) has net assets worth $203.05 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($241.74 Million) and total liabilities ($38.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Invivyd Inc. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $203.05 Million |
| % of Total Assets | 83.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | -56.71% |
| 10-Year Change | N/A |
| Growth Volatility | 133.27 |
Invivyd Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s net assets have evolved over time, based on quarterly financial data. See IVVD defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Invivyd Inc. (2020–2025)
The table below shows the annual net assets of Invivyd Inc. from 2020 to 2025. For live valuation and market cap data, see Invivyd Inc. (IVVD) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $241.54 Million | +257.63% |
| 2024-12-31 | $67.54 Million | -61.94% |
| 2023-12-31 | $177.47 Million | -50.15% |
| 2022-12-31 | $355.97 Million | -36.21% |
| 2021-12-31 | $558.02 Million | +955.21% |
| 2020-12-31 | $-65.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Invivyd Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 88916400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.01% |
| Other Comprehensive Income | $-41.00K | -0.02% |
| Other Components | $1.20 Billion | 495.17% |
| Total Equity | $241.54 Million | 100.00% |
Invivyd Inc. Competitors by Market Cap
The table below lists competitors of Invivyd Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JS Corp
KO:194370
|
$239.39 Million |
|
ADTechnology Co.Ltd
KQ:200710
|
$239.60 Million |
|
Liaoning Kelong Fine ChemicalInc
SHE:300405
|
$239.69 Million |
|
Canaan Inc
NASDAQ:CAN
|
$239.74 Million |
|
Talbros Automotive Components Limited
NSE:TALBROAUTO
|
$239.26 Million |
|
Tukas Gida Sanayi ve Ticaret AS
IS:TUKAS
|
$238.87 Million |
|
Geojit Financial Services Limited
NSE:GEOJITFSL
|
$238.74 Million |
|
GDI Property Group
AU:GDI
|
$238.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Invivyd Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 67,539,000 to 241,540,000, a change of 174,001,000 (257.6%).
- Net loss of 52,489,000 reduced equity.
- Share repurchases of 633,000 reduced equity.
- New share issuances of 215,934,000 increased equity.
- Other comprehensive income decreased equity by 36,000.
- Other factors increased equity by 11,225,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.49 Million | -21.73% |
| Share Repurchases | $633.00K | -0.26% |
| Share Issuances | $215.93 Million | +89.4% |
| Other Comprehensive Income | $-36.00K | -0.01% |
| Other Changes | $11.22 Million | +4.65% |
| Total Change | $- | 257.63% |
Book Value vs Market Value Analysis
This analysis compares Invivyd Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.59 | $0.93 | x |
| 2021-12-31 | $5.04 | $0.93 | x |
| 2022-12-31 | $3.29 | $0.93 | x |
| 2023-12-31 | $1.62 | $0.93 | x |
| 2024-12-31 | $0.57 | $0.93 | x |
| 2025-12-31 | $1.40 | $0.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Invivyd Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -98.25%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.15x
- Recent ROE (-21.73%) is above the historical average (-82.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-105.45 Million |
| 2021 | -40.64% | 0.00% | 0.00x | 1.11x | $-282.59 Million |
| 2022 | -67.79% | 0.00% | 0.00x | 1.08x | $-276.91 Million |
| 2023 | -111.93% | 0.00% | 0.00x | 1.29x | $-216.39 Million |
| 2024 | -251.60% | -669.42% | 0.20x | 1.92x | $-176.68 Million |
| 2025 | -21.73% | -98.25% | 0.19x | 1.15x | $-76.64 Million |
Industry Comparison
This section compares Invivyd Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Invivyd Inc. (IVVD) | $203.05 Million | 0.00% | 0.19x | $239.37 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more